Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Aptose Biosciences
  • Can-Fite BioPharma Ltd.
  • Celator Pharmaceuticals
  • Celldex Therapeutics Inc.
  • Concert Pharmaceuticals
  • Cytori Therapeutics Inc.
  • DelMar Pharmaceuticals Inc.
  • Dendreon Corp.
  • Flex Pharma
  • GenVec Inc.
  • Isis Pharmaceuticals Inc.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • Palatin Technologies Inc.
  • Rexahn Pharmaceuticals Inc.
  • ROTH Capital Partners
  • Spectrum Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Vericel Corp.
  • Viralytics Ltd.
  • Zosano Pharma Corp.
  • ZZ-OLD Lion Biotechnologies Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

Recent Quotes

"We believe 2015 will see a flurry of activity out of DMPI." (2/18/15) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CANF's Phase 2/3 study of CF101 in plaque psoriasis patients is complete; we believe now is a good time to buy." (2/4/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS shares should perform well in 2015." (12/15/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"DMPI has a valuable, novel asset with distinguishing attributes." (11/17/14) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"In Q3/14, SNSS reported EPS of $0.25, beating our estimate and the consensus." (11/11/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer." (9/24/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We see significant partnering potential for CANF's rheumatoid arthritis drug." (9/2/14) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

more comments

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"RNN's RX-3117 has potential to be a sleeper product candidate." (6/5/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on CYTR." (6/24/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We reinstate our Buy rating on CYTR." (5/31/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"GALE is well positioned for a successful outcome of the phase 3 NeuVax PRESENT study." (5/10/13) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

fewer comments


Due to permission requirements, not all quotes are shown.